Recent searches
Search options
Independent US government and NIH analysis was performed on Novavax's US/Mexico phase 3 clinical trial to determine correlates of risk and correlates of protection 2 weeks after the second dose over the subsequent 7-59 days ( https://www.nature.com/articles/s41467-022-35768-3 ).
This clinical trial was run later than others so the majority of COVID cases were caused by variants, mostly Alpha but also Beta, Gamma, Epsilon, and Iota. Overall they found efficacy of 90%. 5/
NatureImmune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial - Nature CommunicationsAuthors have previously reported on the efficacy and safety of the recombinant spike protein nanoparticle vaccine, NVX-CoV2373, in healthy adults. In this work, they assess anti-spike binding IgG, anti-RBD binding IgG and neutralising antibody titer as correlates of risk and protection against COVID-19.